Erythropoiesis‐Stimulating Agent Use for Anemia Induced by Interferon‐Ribavirin Treatment in Patients with Hepatitis C Virus Infection Is Not Associated with Increased Rates of Cardiovascular Disease, Thrombosis, Malignancy, or Death
Distribution of the number of citations over years.